Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)

European Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2009, Pages 1-2

  Klotz, Ulrich ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AREA UNDER THE CURVE; CYP2C19 GENE; DRUG ACTIVATION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RESPONSE; EDITORIAL; ENZYME ACTIVITY; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE;

ARYL HYDROCARBON HYDROXYLASES; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; OMEPRAZOLE; PHENOTYPE; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 57849099136     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0571-x     Document Type: Editorial

References (14)

1. J Kirchheiner U Fuhr J Brockmöller 2005 Pharmacogenetics-based therapeutic recommendations-ready for clinical practice Nat Rev Drug Discovery 4 639 647
2. Lou H-Y, Chang C-C, Sheu M-T, Chen Y-C, Ho H-O (2008) Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol (in press)
3. U Klotz M Schwab M Treiber 2004 CYP2C19 polymorphism and proton pump inhibitors Basic Clin Pharmacol Toxicol 95 2 8
4. U Klotz 2006 Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem Int J Clin Pharmacol Ther 44 297 302
5. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson M Ingelman-Sundberg 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113
6. O Junghard M Hassan-Alin G Hasselgren 2002 The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH Eur J Clin Pharmacol 58 453 458
7. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951
8. M Schwab U Klotz U Hofmann E Schaeffeler A Leodolter P Malfertheiner G Treiber 2005 Esomeprazole-induced healing of gastrooesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data Clin Pharmacol Ther 78 627 634
9. J Horn 2004 Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole Aliment Pharmacol Ther 20 suppl 6 11 19
10. M Sugimoto T Furuta N Shirai M Kajimura A Hishida MO Sakurai T Ishizaki 2004 Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 78 290 301
11. JS Hulot A Bura E Villard M Azizi V Remones C Goyenvalle M Aiach P Lechat P Gaussen 2006 Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2244 2247
12. D Trenk W Hochholzer MF Fromm L-C Chialda A Pahl CM Valina C Stratz P Schmiebusch HP Bestehorn HJ Buettner F-J Neumann 2008 Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 1925 1934
13. M Gilard B Arnaud J-C Cornily G Le Gal K Lacut G Le Calvez J Mansourati D Mottier J-F Abgrall J Boschat 2008 Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin J Am Coll Cardiol 51 256 260
14. PA Gurbel WC Lau US Tantry 2008 Omeprazole-a possible new candidate influencing the antiplatelet effect of clopidogrel J Am Coll Cardiol 51 261 263